Effects of the N-Terminal Sequence of ACE on the Properties of Its C-Domain
- 1 July 2000
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 36 (1) , 116-121
- https://doi.org/10.1161/01.hyp.36.1.116-a
Abstract
Abstract —Angiotensin I–converting enzyme (ACE, kininase II) has 2 active domains (N and C) in a single peptide chain. Because we found its N-domain more stable than its C-domain, we investigated the effect of the amino-terminus of human ACE on the C-domain with a molecular construct expressed in Chinese hamster ovary cells (CHO) cells and transiently in HEK293 cells. This active N-deleted ACE contained only the first 141 amino acids of the human N-domain but not its active center and was linked to the active C-domain containing the transmembrane and cytosolic portions of ACE. The CHO cells were also transfected with human B 2 bradykinin receptor. ACE inhibitors (5 nmol/L or 1 μmol/L) augmented bradykinin (100 nmol/L) effects, elevated B 2 receptor numbers, and resensitized the receptor desensitized by agonist as measured by arachidonic acid release or [Ca 2+ ] i mobilization. Arachidonic acid release was mediated by pertussis toxin–sensitive Gα i , and [Ca 2+ ] i mobilization was mediated by pertussis-insensitive Gα q protein receptor complex. The properties of the construct were compared with wild-type ACE and separate N- and C-domains. The N-deleted ACE differed from wild-type in activation by Cl − and [SO 4 ] 2− ions, hydrolysis ratios of substrates (both short synthetic and endogenous peptides) and heat stability. Thus, the N-terminal peptide of ACE affected the characteristics of the C-domain active center. ACE inhibitors acting on N-deleted ACE, which had only a single C-domain active center anchored to plasma membrane, induced cross-talk between the enzyme and the B 2 receptor (eg, the inhibitors resensitized the receptor) independent of blocking bradykinin inactivation.Keywords
This publication has 19 references indexed in Scilit:
- Replacement of the Transmembrane Anchor in Angiotensin I-converting Enzyme (ACE) with a Glycosylphosphatidylinositol Tail Affects Activation of the B2 Bradykinin Receptor by ACE InhibitorsJournal of Biological Chemistry, 2000
- Limited Proteolysis of Human Kidney Angiotensin-Converting Enzyme and Generation of Catalytically Active N- and C-Terminal DomainsBiochemical and Biophysical Research Communications, 1997
- Bradykinin Sequesters B2 Bradykinin Receptors and the Receptor-coupled Gα Subunits Gαq and Gαiin Caveolae in DDT1 MF-2 Smooth Muscle CellsPublished by Elsevier ,1997
- Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.Journal of Clinical Investigation, 1996
- The Hemoregulatory Peptide N-Acetyl-Ser-Asp-Lys-Pro Is a Natural and Specific Substrate of the N-terminal Active Site of Human Angiotensin-converting EnzymeJournal of Biological Chemistry, 1995
- The G proteins of the G alpha i and G alpha q family couple the bradykinin receptor to the release of endothelium-derived relaxing factor.Journal of Clinical Investigation, 1993
- Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymesBiochemistry, 1991
- Sulfate potentiation of the chloride activation of angiotensin converting enzymeBiochemistry, 1987
- Human Converting EnzymeClinical and Experimental Hypertension. Part A: Theory and Practice, 1983
- Angiotensin I converting enzyme.Circulation Research, 1975